drugset / Trial / NCT02438761
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Phase 2
Terminated
10 enrolled
Institut Curie
Fondation ARC · collabNational Cancer Institute, France · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase II open-label single-arm prospective multicentric clinical trial of PF-05212384 (PKI-587) delivered by intravenous route. A 2-stage Fleming design will be employed.
Timeline
- Start
- 2015-08-31
- Primary completion
- 2017-05-10
- Completion
- 2018-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gedatolisib | Small molecule | 150 mg | Intravenous |